With the release of its Q Exactive UHMR system and a new $130 million NIH program, the company sees opportunity to expand use of its cryo-EM and mass spec techs.
Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.
The study combined large-scale protein post-translational modification datasets with protein-protein interaction data to profile cell signaling in lung cancer.
Developed in the lab of Max Planck's Matthias Mann, the approach adjusts the sampling of ions during the initial scan to boost assay sensitivity and reproducibility.
The company reported total revenues of $431.7 million for the three months ended March 31, beating analysts' consensus estimate of $417.4 million.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
Based on the strong first quarter results, the company raised its revenue and earnings guidance for the year.
Organic revenues were up 2 percent, as the company saw solid demand among its pharma customers but a decline in sales of its mass spectrometry instruments.
The study used analysis of intact proteins to identify mutation-linked post-translational modifications involved in KRAS activation and membrane attachment.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
While mass spec-based single-cell proteomics is still in its infancy, recently developed methods allow the ID of thousands of proteins at the single-cell level.
The tool uses linear algebra to analyze convoluted DIA mass spectra and could boost the sensitivity and accuracy of DIA analyses, its developers said.
Smith, an assistant professor of computer science, recently published a study in Journal of Proteome Research on how mass spec users see their software options.
The multiplexed proteomic approach could offer better sensitivity and accuracy than existing methods while working with a wider range of instrumentation.
The companies are aiming to codevelop, comarket, and improve the integration of the Evosep One LC system with Bruker's timsTOF Pro mass spec.
The approach allows for more confident identification of peptide variants and enables deeper and broader peptide coverage, according to the researchers.
The UK startup believes protein PTMs can provide insights into protein damage that can be used to address common late-onset conditions like atherosclerosis.
Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.
The API assets could enable more data-intensive, machine learning-based approaches to healthcare, said a principal at DiscernDx investor Khosla Ventures.
The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.